down arrow

Sai Life

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE570L01029
  • NSEID: SAILIFE
  • BSEID: 544306
INR
667.30
27.15 (4.24%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 96.05 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Sai Life Sciences Ltd stock-summary
stock-summary
Sai Life Sciences Ltd
Mid Cap
Pharmaceuticals & Drugs
Sai Life Sciences Limited was originally incorporated as `Sai Dru Syn Laboratories Limited' as a Public Limited Company, dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. The Company received the Certificate of Commencement of Business from Registrar of Companies, Andhra Pradesh on February 17, 1999. Subsequently, the Company name was changed from `Sai Dru Syn Laboratories Limited' to `Sai Life Sciences Limited' dated December 16, 2003.
Company Coordinates stock-summary
Icon
No Company Details Available
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR None Cr
Number of Shares
None Cr
Face Value
INR None
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

2.6885

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Mytreyi Kanumuri Partner Of Marigold Partners (partnership Firm) (10.67%)

Highest Public shareholder

Tpg Asia Vii Sf Pte Ltd (24.78%)

Individual Investors Holdings

stock-summary Board of Directors
stock-summary
stock-summary
Management
Designation
Remuneration
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
 
Icon
No Data Available
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
440 Cr
(Quarterly Results - Dec 2024)
Net Profit:
54 Cr
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 13,907 Cr (Mid Cap)

stock-summary
P/E

140.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.56

stock-summary
Return on Equity

9.52%

stock-summary
Price to Book

13.33